WellPoint Still Glowing
WellPoint (WLP) has received a second, more favorable opinion of its 2006 guidance.
True, the company simply reiterated its outlook -- rather than raising it to meet lofty Wall Street expectations -- during its much-awaited investor day this week. But the company has a reputation for beating its own targets, so some experts on Wednesday chose to leave their own, more bullish views intact.
"Since we are paid to produce our best estimates and not simply repeat management statements, we will ignore this guidance," declared Prudential analyst David Shove. "We continue to believe that the synergies from the Anthem deal and the profitability of (Medicare) Part D will drive earnings to $4.80 in 2006. We reiterate our overweight rating for the shares."
Several other analysts viewed WellPoint's 2006 forecast, calling for operating profits of $4.69 a share, as conservative as well.
Patrick Hojlo of Credit Suisse First Boston pointed to history as a guide. Last year, he noted, WellPoint projected higher costs -- and ultimately, lower earnings -- than have materialized. Now, he suggests, the company seems even better positioned to capitalize on favorable industry trends and deliver additional upside going forward. In the meantime, however, shares of WellPoint have taken a slight hit. The stock, which was trading near an all-time high ahead of this week's update, slipped 1.7% to $77.71 Wednesday. But Hojlo wasn't necessarily surprised. "When your stock is up 38% year-to-date -- and 120% over the past two years -- expectations can be hard to beat," he wrote on Tuesday. "The market may have wanted a little more from WLP today in the way of guidance. But ... (because of) our belief that the company will grow operating profit faster than the market currently expects -- 12% to 15% -- over the next three to five years, we are still confident buyers of the stock."Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV